Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:57:45.521Z.
Calculation as of: 2026-10-06T16:57:45.521Z.
Quote observation: 2026-10-06T16:54:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a9e17458a879267a616e624bc5dc95fe16f3f590d16343b45edf8fcc71148c1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$355.34M
EBITDA Yield
N/A
TTM Avg
3.28%
3Y Avg
4.15%
5Y Avg
7.65%
Market Cap
$355.01M
EBITDA Yield
N/A
TTM Avg
3.23%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$353.96M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.70M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$374.20M
EBITDA Yield
N/A
TTM Avg
0.15%
3Y Avg
0.15%
5Y Avg
0.15%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $361.15M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $355.34M | N/A | 3.28% | 4.15% | 7.65% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.01M | N/A | 3.23% | 3.23% | 3.23% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $353.96M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $361.60M | 18.51% | 21.70% | 14.93% | 15.13% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $349.81M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $362.98M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.20M | N/A | 0.15% | 0.15% | 0.15% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $380.87M | N/A | 12.83% | 12.83% | 12.83% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
